Report
Louis AZAIS
EUR 97.56 For Business Accounts Only

Analyse court terme - GLAXOSMITHKLINE : Les prix dépassent la moyenne mobile, c'est un signal de force.

La résistance vient d'être franchie, la tendance devient positive puisque nous avons maintenant une succession de sommets et de creux ascendants. Le prochain objectif est à 1 495,00 p. Le niveau d'invalidation est sous 1 369,00 p.

Arguments :
- Les cours ont fait un pull-back sur le support (ancienne résistance), la hausse reprend.
- Les prix dépassent la moyenne mobile, c'est un signal de force.
Underlying
GlaxoSmithKline plc

GlaxoSmithKline is a global healthcare company. Co.'s segments include: Pharmaceuticals; Vaccines; and Consumer Healthcare. The Pharmaceuticals segment is focused on developing new medicines in respiratory, HIV, oncology and immuno-inflammation, with discovery research exploring these and other areas. The Vaccines segment has a portfolio and pipeline of vaccines to help protect people throughout life. Co. delivers vaccines to people living in over 160 countries. The Consumer Healthcare segment develops and markets consumer-preferred brands in oral health, pain relief, respiratory, nutrition/gastro-intestinal and skin health.

Provider
Day By Day
Day By Day

​​DayByDay is an independent research company providing global macro and single stock analysis, recommendation and allocation based purely on behavioural finance methods. Those include long term cycle analysis, sentiment analysis, and technical trigger. DayByDay serves all clients in need of practical and precise publications to make effective market decisions, on any time horizon, from a few hours to a few years.

Analysts
Louis AZAIS

Other Reports on these Companies
Other Reports from Day By Day

ResearchPool Subscriptions

Get the most out of your insights

Get in touch